查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030年bupivacaine hydrochloride注射液全球市場預測：依濃度、容量、包裝、應用、最終用戶及地區分析
市場調查報告書
商品編碼
1383322

2030年bupivacaine hydrochloride注射液全球市場預測：依濃度、容量、包裝、應用、最終用戶及地區分析

Bupivacaine Hydrochloride Injection Market Forecasts to 2030 - Global Analysis By Concentration, Volume (Small Volume, Medium Volume and Large Volume ), Packaging, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC的數據，2023年全球bupivacaine hydrochloride注射液市場規模為11.2021億美元，預計到2030年將達到18.7027億美元，預測期內年複合成長率為7.6%。

bupivacaine hydrochloride注射液是一種用於麻醉和疼痛管理領域的藥物。透過給藥給予局部麻醉劑，使身體的某些部位麻木。布比卡因的作用是阻斷疼痛訊號沿著神經纖維的傳遞。布比卡因應謹慎給藥，尤其是高風險病患或需要密切監測的情況下。布比卡因不應用於已知對該藥物過敏的患者。

根據美國整形外科學會 (AAOS) 的研究，美國每年進行超過 432,000 例脊椎融合手術。根據醫療保健研究與品質機構的一項研究，美國年度進行超過 79 萬美國膝關節關節重建手術。

對門診手術中心的需求不斷成長

ASC 擴大執行各種外科手術，包括整形外科、眼科、婦科和牙科。這些中心喜歡使用局部麻醉劑，例如bupivacaine hydrochloride注射液，因為它們提供有效的麻醉，同時讓患者快速康復並在當天回家。 ASC 也以其經濟高效的醫療保健服務方式而聞名。鴉片類藥物使用的最小化、副作用風險的降低以及快速治療也正在推動市場成長。

嚴格的法規核准流程

美國FDA 等法規機構為藥品的安全性和有效性制定了高標準。即使在監管核准流程上投入了大量資金，也存在核准被拒絕或延遲的風險。即使在核准後，公司也必須遵守持續的上市後監督和報告要求。因此，法規核准情況可能會影響定價和報銷決策。滿足這些標準至關重要，但對市場來說可能是一個挑戰。

擴大手術程序

無論大小，外科手術通常都需要麻醉，以確保患者在手術過程中的舒適和安全。bupivacaine hydrochloride是一種廣泛使用的局部麻醉劑，可在手術期間和手術後提供有效的鎮痛作用。bupivacaine hydrochloride常用於局部麻醉技術。微創手術的增加通常涉及局部麻醉技術。廣泛的外科專業和微創手術的應用正在推動市場成長。

與學名藥的競爭

bupivacaine hydrochloride布比卡因注射液的學名藥通常以比品牌產品更低的價格進入市場。這可能會導致價格競爭並降低先發製造商的報酬率。有時這會導致製造商之間合併、收購和聯盟，以實現規模經濟並保持盈利。它還可能導致市場飽和。所有這些因素都阻礙了市場需求。

COVID-19 的影響

COVID-19大流行對製藥業產生了多種影響。由於工廠關閉、運輸限制和勞動力短缺，疫情導致全球供應鏈中斷。這影響了bupivacaine hydrochloride注射液的可用性和分銷。在疫情高峰期，許多擇期手術被推遲或取消，以節省資源並降低感染風險。這場大流行也引起了人們對醫療保健中有效疼痛管理的重要性的關注。這可能會對醫療保健利用模式產生長期影響，並影響對bupivacaine hydrochloride注射液等產品的需求。

慢性疼痛管理領域預計將成為預測期內最大的領域

慢性疼痛管理領域預計將出現良好的成長。bupivacaine hydrochloride常用於硬脊膜外麻醉和神經阻斷等局部麻醉。它可以緩解身體特定部位的疼痛，而不會導致意識喪失。與其他局部麻醉劑相比，bupivacaine hydrochloride的全身吸收率較低。它們更長的作用時間、維持肌肉力量以及提高患者舒適度和滿意度正在推動這一領域的需求。

預計專科診所和疼痛管理中心領域在預測期內的年複合成長率最高

預計專科診所和疼痛管理中心部門在預測期內將出現最高的年複合成長率。bupivacaine hydrochloride注射是疼痛管理中心的寶貴武器，為緩解疼痛、增加患者舒適度和幫助復原提供了可靠有效的方法。布比卡因比其他局部麻醉劑的作用持續時間更長。由於其作用時間長，布比卡因在門診和手術後需要長時間緩解疼痛的門診病人中特別有用。

比最大的地區

預計亞太地區在預測期內將佔據最大的市場佔有率。由於人口成長、醫療保健機會的改善和高齡化因素，亞太地區的外科手術數量不斷增加。中國、印度、日本、韓國和澳洲正在大力投資衛生基礎設施。隨著先進醫療技術和醫療設備的引進，該地區的外科治療品質不斷提高。此外，對疼痛管理的認知不斷提高以及強大的主要企業的存在正在推動市場需求。

複合年複合成長率最高的地區：

預計北美在預測期內的年複合成長率最高。該地區以其醫療保健技術進步而聞名。隨著北美高齡化老化，慢性疼痛呈現上升趨勢。北美的外科手術比例也很高，包括選擇性和非選擇性手術。此外，該地區的藥品市場競爭非常激烈，既有非專利藥製造商，也有品牌製造商。此外，研發配合措施和激烈的市場競爭正在推動北美市場的發展。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球bupivacaine hydrochloride注射液市場：依濃度分類

  • 介紹
  • 0.25%
  • 0.50%
  • 0.75%
  • 其他濃度

第6章 全球bupivacaine hydrochloride注射液市場：依數量

  • 介紹
  • 小容量（5ML）
  • 中容量（10ML）
  • 大容量（20ML以上）

第7章 全球bupivacaine hydrochloride注射液市場：依包裝分類

  • 介紹
  • 單給藥小瓶
  • 多劑量小瓶
  • 安瓿

第8章 全球bupivacaine hydrochloride注射液市場：依應用分類

  • 介紹
  • 手術麻醉
  • 產科麻醉
  • 慢性疼痛管理
  • 整形外科手術
  • 心血管手術
  • 神經治療
  • 牙科手術
  • 其他用途

第9章 全球bupivacaine hydrochloride注射液市場：依最終用戶分類

  • 介紹
  • 日間手術中心 (ASC)
  • 醫院和診所
  • 專科診所和疼痛管理中心
  • 牙醫診所
  • 其他最終用戶

第10章 全球bupivacaine hydrochloride注射液市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第11章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章公司簡介

  • Hikma Pharmaceuticals
  • Pfizer Inc.
  • Fresenius Kabi AG
  • Baxter International Inc.
  • AstraZeneca
  • AuroMedics Pharma LLC
  • Areva
  • SteriMax Inc.
  • Shanghai Harvest Pharmaceutical Co.
  • Southwest Pharma
  • Hunan Kelun Pharmaceutical
  • Aurobindo pharma
  • Sagent Pharmaceuticals
Product Code: SMRC24172

According to Stratistics MRC, the Global Bupivacaine Hydrochloride Injection Market is accounted for $1120.21 million in 2023 and is expected to reach $1870.27 million by 2030 growing at a CAGR of 7.6% during the forecast period. Bupivacaine Hydrochloride Injection is a medication used in the field of anaesthesia and pain management. It is a local anaesthetic that is administered via injection to numb specific areas of the body. Bupivacaine works by blocking the transmission of pain signals along nerve fibers. Bupivacaine should be administered with caution, especially in high-risk patients or in situations where close monitoring is required. Bupivacaine should not be used in patients with known allergies to the drug.

According to the American Academy of Orthopedic Surgeons (AAOS) survey, over 432,000 spinal fusions are performed in the United States every year. As per the Agency for Healthcare Research and Quality, more than 790,000 knee replacements are performed yearly in the United States.

Market Dynamics:

Driver:

Rising demand for ambulatory surgical centers

ASCs are increasingly performing a wide range of surgical procedures, including orthopedic, ophthalmic, gynaecological, and dental surgeries. These centers often prefer using local anaesthetics like Bupivacaine Hydrochloride Injection for their ability to provide effective anaesthesia while allowing patients to recover quickly and go home on the same day. Also, ASCs are known for their cost-effective approach to healthcare delivery. As well as, its minimization of opioid usage, reduced risk of side effects and quick turnaround times are fuelling the market growth.

Restraint:

Stringent regulatory approval process

Regulatory authorities, such as the FDA in the United States, set high safety and efficacy standards for medications. Even after significant investment in the regulatory approval process, there is a risk of rejection or delays in approval. Even after approval, companies must comply with ongoing post-market surveillance and reporting requirements. Therefore, regulatory approval status can influence pricing and reimbursement decisions. Meeting these standards is essential but can be challenging for the market.

Opportunity:

Growing surgical procedures

Surgical procedures, whether major or minor, typically require anaesthesia to ensure patient comfort and safety during the operation. Bupivacaine Hydrochloride is a widely used local anaesthetic that provides effective pain relief during and after surgery. Bupivacaine Hydrochloride is commonly used in regional anaesthesia techniques. The rise in minimally invasive surgical procedures often involves regional anaesthesia techniques. Its applications in wide range of surgical specialties and minimally invasive procedures are propelling the market growth.

Threat:

Competition from generic versions

Generic versions of bupivacaine hydrochloride injections typically enter the market at lower prices than their branded counterparts. This can lead to price competition and erosion of profit margins for the original manufacturer. This may prompt mergers, acquisitions, or partnerships among manufacturers to achieve economies of scale and maintain profitability. It can also lead to market saturation. All these elements hinder the market demand.

COVID-19 Impact

The COVID-19 pandemic had several impacts on the pharmaceutical industry. The pandemic led to disruptions in global supply chains due to lockdowns, restrictions on transportation, and workforce shortages. This affected the availability and distribution of Bupivacaine Hydrochloride Injection. Many elective surgeries were postponed or cancelled during the peak of the pandemic to conserve resources and reduce the risk of transmission. Also, the pandemic brought attention to the importance of effective pain management in healthcare. So, there may be longer-term effects on healthcare utilization patterns, which could influence the demand for products like Bupivacaine Hydrochloride Injection.

The chronic pain management segment is expected to be the largest during the forecast period

The chronic pain management segment is estimated to have a lucrative growth. Bupivacaine Hydrochloride is often used in regional anaesthesia techniques such as epidural and nerve block procedures. It provides pain relief in specific areas of the body without causing a loss of consciousness. Compared to some other local anaesthetics, bupivacaine hydrochloride has a lower rate of systemic absorption. Its longer duration of action, preservation of muscle strength, enhanced patient comfort and satisfaction drives the segment demand.

The specialty clinics & pain management centers segment is expected to have the highest CAGR during the forecast period

The specialty clinics & pain management centers segment is anticipated to witness the highest CAGR growth during the forecast period. Bupivacaine Hydrochloride Injection is a valuable tool in the arsenal of pain management centers, offering a reliable and effective means to alleviate pain, enhance patient comfort, and support rehabilitation efforts. Bupivacaine has a longer duration of action compared to some other local anaesthetics. Due to its prolonged duration of action, bupivacaine can be especially useful in ambulatory or outpatient settings where extended pain relief is needed after a procedure.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period. The Asia-Pacific region has witnessed a rise in surgical procedures, driven by factors such as population growth, increased access to healthcare, and a rising aging population. China, India, Japan, South Korea, and Australia, have been investing significantly in their healthcare infrastructure. The adoption of advanced medical technologies and equipment has improved the quality of surgical care in the region. Further, the rising awareness of pain management and presence of strong key players are fuelling the market demand.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. The region is well known for its technological advancements in healthcare. The aging population in North America has led to an increase in chronic pain conditions. Also, North America has a high rate of surgical procedures, including both elective and non-elective surgeries. In addition, the market for pharmaceuticals in the region is highly competitive, with both generic and brand-name manufacturers. Further, its research and development initiatives and strong market competition is boosting the North American market.

Key players in the market

Some of the key players profiled in the Bupivacaine Hydrochloride Injection Market include: Hikma Pharmaceuticals, Pfizer Inc., Fresenius Kabi AG, Baxter International Inc., AstraZeneca, AuroMedics Pharma LLC, Areva, SteriMax Inc., Shanghai Harvest Pharmaceutical Co., Southwest Pharma, Hunan Kelun Pharmaceutical, Aurobindo pharma and Sagent Pharmaceuticals.

Key Developments:

In December 2021, Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, announced that it launched Bupivacaine HCl Injection, USP through its US affiliate, Hikma Pharmaceuticals USA Inc.

In July 2016, India-based pharmaceutical manufacturing company, Aurobindo pharma has got approval from the US food and drug administration (USFDA) to produce and market its anaesthetic Bupivacaine Hydrochloride injection in the American market.

Concentrations Covered:

  • 0.25%
  • 0.50%
  • 0.75%
  • Other Concentrations

Volumes Covered:

  • Small Volume (5 ML)
  • Medium Volume (10 ML)
  • Large Volume (>20 ML)

Packagings Covered:

  • Single-Dose Vials
  • Multi-Dose Vials
  • Ampoules

Applications Covered:

  • Surgical Anaesthesia
  • Obstetric Anaesthesia
  • Chronic Pain Management
  • Orthopedic Procedures
  • Cardiovascular Procedures
  • Neurological Procedures
  • Dental Procedures
  • Other Applications

End Users Covered:

  • Ambulatory Surgical Centers (ASCs)
  • Hospitals & Clinics
  • Specialty Clinics & Pain Management Centers
  • Dental Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Bupivacaine Hydrochloride Injection Market, By Concentration

  • 5.1 Introduction
  • 5.2 0.25%
  • 5.3 0.50%
  • 5.4 0.75%
  • 5.5 Other Concentrations

6 Global Bupivacaine Hydrochloride Injection Market, By Volume

  • 6.1 Introduction
  • 6.2 Small Volume (5 ML)
  • 6.3 Medium Volume (10 ML)
  • 6.4 Large Volume (>20 ML)

7 Global Bupivacaine Hydrochloride Injection Market, By Packaging

  • 7.1 Introduction
  • 7.2 Single-Dose Vials
  • 7.3 Multi-Dose Vials
  • 7.4 Ampoules

8 Global Bupivacaine Hydrochloride Injection Market, By Application

  • 8.1 Introduction
  • 8.2 Surgical Anesthesia
  • 8.3 Obstetric Anesthesia
  • 8.4 Chronic Pain Management
  • 8.5 Orthopedic Procedures
  • 8.6 Cardiovascular Procedures
  • 8.7 Neurological Procedures
  • 8.8 Dental Procedures
  • 8.9 Other Applications

9 Global Bupivacaine Hydrochloride Injection Market, By End User

  • 9.1 Introduction
  • 9.2 Ambulatory Surgical Centers (ASCs)
  • 9.3 Hospitals & Clinics
  • 9.4 Specialty Clinics & Pain Management Centers
  • 9.5 Dental Clinics
  • 9.6 Other End Users

10 Global Bupivacaine Hydrochloride Injection Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Hikma Pharmaceuticals
  • 12.2 Pfizer Inc.
  • 12.3 Fresenius Kabi AG
  • 12.4 Baxter International Inc.
  • 12.5 AstraZeneca
  • 12.6 AuroMedics Pharma LLC
  • 12.7 Areva
  • 12.8 SteriMax Inc.
  • 12.9 Shanghai Harvest Pharmaceutical Co.
  • 12.10 Southwest Pharma
  • 12.11 Hunan Kelun Pharmaceutical
  • 12.12 Aurobindo pharma
  • 12.13 Sagent Pharmaceuticals

List of Tables

  • Table 1 Global Bupivacaine Hydrochloride Injection Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Bupivacaine Hydrochloride Injection Market Outlook, Concentration (2021-2030) ($MN)
  • Table 3 Global Bupivacaine Hydrochloride Injection Market Outlook, 0.25% (2021-2030) ($MN)
  • Table 4 Global Bupivacaine Hydrochloride Injection Market Outlook, 0.50% (2021-2030) ($MN)
  • Table 5 Global Bupivacaine Hydrochloride Injection Market Outlook, 0.75% (2021-2030) ($MN)
  • Table 6 Global Bupivacaine Hydrochloride Injection Market Outlook, Other Concentrations (2021-2030) ($MN)
  • Table 7 Global Bupivacaine Hydrochloride Injection Market Outlook, Volume (2021-2030) ($MN)
  • Table 8 Global Bupivacaine Hydrochloride Injection Market Outlook, Small Volume (5 ML) (2021-2030) ($MN)
  • Table 9 Global Bupivacaine Hydrochloride Injection Market Outlook, Medium Volume (10 ML) (2021-2030) ($MN)
  • Table 10 Global Bupivacaine Hydrochloride Injection Market Outlook, Large Volume (>20 ML) (2021-2030) ($MN)
  • Table 11 Global Bupivacaine Hydrochloride Injection Market Outlook, Packaging (2021-2030) ($MN)
  • Table 12 Global Bupivacaine Hydrochloride Injection Market Outlook, Single-Dose Vials (2021-2030) ($MN)
  • Table 13 Global Bupivacaine Hydrochloride Injection Market Outlook, Multi-Dose Vials (2021-2030) ($MN)
  • Table 14 Global Bupivacaine Hydrochloride Injection Market Outlook, Ampoules (2021-2030) ($MN)
  • Table 15 Global Bupivacaine Hydrochloride Injection Market Outlook, Application (2021-2030) ($MN)
  • Table 16 Global Bupivacaine Hydrochloride Injection Market Outlook, Surgical Anesthesia (2021-2030) ($MN)
  • Table 17 Global Bupivacaine Hydrochloride Injection Market Outlook, Obstetric Anesthesia (2021-2030) ($MN)
  • Table 18 Global Bupivacaine Hydrochloride Injection Market Outlook, Chronic Pain Management (2021-2030) ($MN)
  • Table 19 Global Bupivacaine Hydrochloride Injection Market Outlook, Orthopedic Procedures (2021-2030) ($MN)
  • Table 20 Global Bupivacaine Hydrochloride Injection Market Outlook, Cardiovascular Procedures (2021-2030) ($MN)
  • Table 21 Global Bupivacaine Hydrochloride Injection Market Outlook, Neurological Procedures (2021-2030) ($MN)
  • Table 22 Global Bupivacaine Hydrochloride Injection Market Outlook, Dental Procedures (2021-2030) ($MN)
  • Table 23 Global Bupivacaine Hydrochloride Injection Market Outlook, Other Applications (2021-2030) ($MN)
  • Table 24 Global Bupivacaine Hydrochloride Injection Market Outlook, End User (2021-2030) ($MN)
  • Table 25 Global Bupivacaine Hydrochloride Injection Market Outlook, Ambulatory Surgical Centers (ASCs) (2021-2030) ($MN)
  • Table 26 Global Bupivacaine Hydrochloride Injection Market Outlook, Hospitals & Clinics (2021-2030) ($MN)
  • Table 27 Global Bupivacaine Hydrochloride Injection Market Outlook, Specialty Clinics & Pain Management Centers (2021-2030) ($MN)
  • Table 28 Global Bupivacaine Hydrochloride Injection Market Outlook, Dental Clinics (2021-2030) ($MN)
  • Table 29 Global Bupivacaine Hydrochloride Injection Market Outlook, Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.